Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.47 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30509 | 0.77 | MAPT (0.51) | GRIN2BALDH1A1MBTD1L3MBTL3L3MBTL1 | |
| SCHEMBL8613090 | 0.77 | DRD2 (0.49) | SLC6A2SLC6A3GRIN2BALDH1A1MBTD1 | |
| SCHEMBL11980118 | 0.76 | GRIN2B (0.57) | GRIN2BALDH1A1MBTD1L3MBTL3L3MBTL1 | |
| SCHEMBL20759858 | 0.76 | GRIN2B (0.57) | GRIN2BALDH1A1MBTD1L3MBTL3L3MBTL1 | |
| SCHEMBL11980119 | 0.76 | GAA (0.50) | GRIN2BALDH1A1MBTD1L3MBTL3L3MBTL1 | |
| SCHEMBL14161697 | 0.75 | GRIN2B (0.76) | GRIN2BALDH1A1MBTD1L3MBTL3L3MBTL1 | |
| SCHEMBL13648726 | 0.72 | L3MBTL3 (0.72) | GRIN2BALDH1A1MBTD1L3MBTL3L3MBTL1 | |
| SCHEMBL13648728 | 0.72 | L3MBTL3 (0.72) | GRIN2BALDH1A1MBTD1L3MBTL3L3MBTL1 | |
| SCHEMBL20760976 | 0.71 | GRIN2B (0.59) | GRIN2BALDH1A1MBTD1L3MBTL3L3MBTL1 | |
| SCHEMBL22848097 | 0.70 | L3MBTL3 (0.70) | GRIN2BALDH1A1MBTD1L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10695449-B2 | Catalytic radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190054198-A1 | CATALYTIC RADIOFLUORINATION | THE GENERAL HOSPITAL CORPORATION | 2019-02-21 | — | — | US | disclosed |
| US-10098974-B2 | Catalytic radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2018-10-16 | — | — | US | disclosed |
| US-10058625-B2 | Catalytic radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2018-08-28 | — | — | US | disclosed |
| US-20150283273-A1 | Catalytic Radiofluorination | THE GENERAL HOSPITAL CORPORATION | 2015-10-08 | — | — | US | disclosed |
| US-20150132223-A1 | Catalytic Radiofluorination | THE GENERAL HOSPITAL CORPORATION | 2015-05-14 | — | — | US | disclosed |
| US-9017724-B2 | Catalytic radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2015-04-28 | — | — | US | disclosed |
| US-8900550-B2 | Catalytic radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2014-12-02 | — | — | US | disclosed |
| EP-2610234-A1 | Catalytic radiofluorination | The General Hospital Corporation (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20130115168-A1 | Catalytic Radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| EP-1725269-B1 | CATALYTIC RADIOFLUORINATION | GEN HOSPITAL CORP (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8257680-B1 | Catalytic radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2012-09-04 | — | — | US | disclosed |
| US-20120207677-A1 | CATALYTIC RADIOFLUORINATION | THE GENERAL HOSPITAL CORPORATION | 2012-08-16 | — | — | US | disclosed |
| EP-2388017-A2 | Catalytic radiofluorination | The General Hospital Corporation (US) | 2011-11-23 | — | — | EP | disclosed |
| US-8040117-B2 | Closed loop negative feedback system with low frequency modulated gain | FLEXTRONICS AP, LLC (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100215578-A1 | Catalytic Radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2010-08-26 | — | — | US | disclosed |
| US-7632485-B2 | Catalytic radiofluorination | MASSACHUSETTS GENERAL HOSPITAL (US) | 2009-12-15 | — | — | US | disclosed |
| US-20050260130-A1 | Arylphosphonium compounds containing fluorine-18 that are useful as imaging agents; in particular, the phosphonium compound is a tetraaryl phosphonium salt, [F-18]-(4-fluorophenyl)triphenylphosphonium nitrate; Position Emission Tomography | MASSACHUSETTS GENERAL HOSPITAL (US) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130115168-A1 | Catalytic Radiofluorination | ARSA, STS, KCNK18 | SLC6A2 1152/4885SLC6A3 575/4885GRIN2B 4059/4885 |
| US-10098974-B2 | Catalytic radiofluorination | ARSA, STS, KCNK18 | SLC6A2 1152/4885SLC6A3 575/4885GRIN2B 4059/4885 |
| US-10058625-B2 | Catalytic radiofluorination | KCNJ5, KCNQ5, KCNK18 | SLC6A2 2257/4885SLC6A3 1817/4885GRIN2B 4487/4885 |
| US-20190054198-A1 | CATALYTIC RADIOFLUORINATION | KCNJ5, KCNQ5, KCNK18 | SLC6A2 2257/4885SLC6A3 1817/4885GRIN2B 4487/4885 |
| US-20050260130-A1 | Arylphosphonium compounds containing fluorine-18 that are useful as imaging agents; in particular, the phosphonium compound is a tetraaryl phosphonium salt, [F-18]-(4-fluorophenyl)triphenylphosphonium nitrate; Position Emission Tomography | KCNK18, KCNJ5, KCNQ5 | SLC6A2 377/4885SLC6A3 373/4885GRIN2B 3399/4885 |
| US-20150283273-A1 | Catalytic Radiofluorination | KCNJ5, KCNQ5, KCNK18 | SLC6A2 2257/4885SLC6A3 1817/4885GRIN2B 4487/4885 |
| US-10695449-B2 | Catalytic radiofluorination | KCNJ5, KCNQ5, KCNK18 | SLC6A2 2257/4885SLC6A3 1817/4885GRIN2B 4487/4885 |
| US-20100215578-A1 | Catalytic Radiofluorination | KCNJ5, KCNQ5, KCNK18 | SLC6A2 2257/4885SLC6A3 1817/4885GRIN2B 4487/4885 |
| US-20150132223-A1 | Catalytic Radiofluorination | ARSA, KCNK18, STS | SLC6A2 1258/4885SLC6A3 780/4885GRIN2B 3857/4885 |
| US-20120207677-A1 | CATALYTIC RADIOFLUORINATION | ARSA, STS, KCNK18 | SLC6A2 1152/4885SLC6A3 575/4885GRIN2B 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.